The myelodysplastic syndromes (MDS) share their origin in the hematopoietic stem cell but
have otherwise very heterogeneous biological and genetic characteristics. Clinical features …

Background Population-based information on cancer incidence, prevalence and outcome
are required to inform clinical practice and research; but contemporary data are lacking for …

Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell (HSC) disorders
predominating in the elderly, characterised by ineffective haematopoiesis leading to blood …

Background Myelodysplastic syndromes (MDS) are malignant stem-cell diseases that are
usually diagnosed in elderly patients who present with anemia or, less commonly, bi-or …

Platelet transfusions are used in clinical practice to prevent and treat haemorrhage in
thrombocytopenic patients or patients with severe platelet dysfunction. In the UK, and …

Many patients with lower‐risk myelodysplastic syndrome (MDS) experience anaemia, which
has negative consequences. Erythropoiesis‐stimulating agents (ESA s) and their biosimilars …

Simple Summary The world population is genetically and environmentally diverse. In
particular, genetic differences related to an ethnic factor may underlie differences in cancer …

Simple Summary Several novel therapies are being developed to improve the management
of patients with myelodysplastic syndromes. They include drugs aimed at improving …

Background Studies with long-term follow-up of patients with myelodysplastic syndromes
(MDS) based on data from nationwide population-based cancer registries are lacking. We …

Romiplostim can improve platelet counts in about 50% of patients with low‐or intermediate 1‐
risk (lower risk) myelodysplastic syndromes (MDS) and thrombocytopenia, but its long‐term …